Cover Image
Market Research Report

Bioelectronic Medicine 2017-2027

Published by IDTechEx Ltd. Product code 554911
Published Content info 224 Slides
Delivery time: 1-2 business days
Price
Back to Top
Bioelectronic Medicine 2017-2027
Published: September 11, 2017 Content info: 224 Slides
Description

Title:
Bioelectronic Medicine 2017-2027
Cardiac Rhythm and Nerve Stimulator Devices, the Electric Future of Medicine.

The market for Bioelectronic medicines may reach $21 billion by 2027

Bioelectronic medicines hold the potential to change the way in which chronic diseases/ conditions are treated. Instead of taking a molecular medication (pharmaceutical), a tiny implantable electronic device will be the medication. Such device will use electrical stimulation as its form of therapy, presently, bioelectronic medicines are amongst us today they primarily treat cardiovascular diseases, neurological diseases and neurological conditions (chronic pain). In the future, bioelectronic medicines will be smaller, more sophisticated and will treat all known chronic diseases/ conditions known to man, these can be termed 'next generation' bioelectronic medicines.

More precisely, next generation bioelectronic medicines are expected to be the size of a grain of rice, they will be attached to a nerve within the peripheral nervous system that is implicated in a disease or disorder. They will function to change or restore faulty electrical signals in such nerve which will restore the proper function of the 'disordered' organ. Essentially, next generation bioelectronic medicines will read and write the electrical signals within the nervous system, they then will not only be therapeutics but sensors as well. Key drivers for this field are an aging population, an increase in chronic disease and an unmet need that current medical standards of care (pharmaceuticals, physical therapy, etc) have not met. The current market value for bioelectronic medicine is an estimated 15 B USD, this number will conservatively increase in the up and coming years.

While this market is saturated, efforts in the continuation of bioelectronic medicines have offered a plethora of opportunities for new entrants. Next generation bioelectronic medicines are currently in development, meaning no true next generation bioelectronic medicine has hit the market as of now. Researchers, as well as some start-up companies, are heavily invested in their development; the materials, design and functional capabilities needed to fabricate these sophisticated next generation bioelectronic medicines are being brainstormed. Therefore, researchers and pivotal players in this field are open to innovative ideas regarding materials, design and functionality of these devices.

In this report, a 10-year forecast is given, the key players in present day and future bioelectronic medicines are identified and targeted. The report is inclusive of the worldwide potential with the united states leading the way. Research methods were inclusive of attending pertinent conferences related to this topic, patent searches, scoping through annual reports, speaking to experts within this field as well as interviewing relevant companies within this realm.

Analyst access from IDTechEx

All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.

Table of Contents

Table of Contents

1. EXECUTIVE SUMMARY

  • 1.1. Bioelectronic Medicines: Defined
  • 1.2. Why Bioelectric medicine? Side-effects
  • 1.3. Market value of current day bioelectronic medicines: 2017-2027
  • 1.4. Market potential: Next generation bioelectronic medicines
  • 1.5. Pictorial representation of 'Bioelectronic medicine' devices
  • 1.6. Trends: Bioelectronic medicine
  • 1.7. Investment in the development of advanced bioelectric medicine
    • 1.7.1. Sample of some of the investments that have been made for the development of next-generation bioelectronic medicines
  • 1.8. Market segmentation : 'Bioelectronic medicine'
  • 1.9. Key Players: By Product Type
  • 1.10. Forecasted market maturity level

2. INTRODUCTION

  • 2.1. Introduction: Scope of report
    • 2.1.1. Introduction: Initiation, emergence and trends in bioelectronic medicines
  • 2.2. Definitions : Assortment of commonly used terms throughout this report
  • 2.3. Disease: Disordered function within the body
  • 2.4. Neurological disorder: Pain
  • 2.5. Chronic Disease: Prevalence of diabetes, current and years to come
  • 2.6. Molecular structures : Pharmaceuticals as treatments for disease
    • 2.6.1. Molecular structures : Applications and methods of delivery for pharmaceuticals
    • 2.6.2. Molecular structures : The path of pharmaceuticals in the body
  • 2.7. Electrical impulse medicines: Origins of electrical stimulation as a therapy in the treatment of disease and medical conditions
    • 2.7.1. Electrical impulse medicines: The nervous system
    • 2.7.2. Electrical impulse: Peripheral nervous system
  • 2.8. Market segmentation : ‘Bioelectronic medicine'
    • 2.8.1. Market Segmentation: Product
    • 2.8.2. Market Segmentation : Disease indications
    • 2.8.3. Market Segmentation: Product type
    • 2.8.4. Market Segmentation : End-user
    • 2.8.5. Market Segmentation: Geographical region
  • 2.9. Institutions and industries acting on new developments in next generation bioelectronic medicines
  • 2.10. Collaboration : Overlap between different industries and institutions
  • 2.11. Headlines : Prominent headlines concerning bioelectronic medicine, 2013-2017
  • 2.12. Google Trends: "Bioelectronic medicine"
  • 2.13. Timeline: illustration of the design and applicable disease indications of bioelectronic medicine from 1842- current date
  • 2.14. Forecasted market maturity level

3. MARKET DYNAMICS: TRENDS AND DRIVERS

  • 3.1. Trends: Bioelectronic medicine
  • 3.2. Investment in the development of advanced bioelectric medicine
    • 3.2.1. Investments: Anticipated investment from government agencies for the FY2017 Federal agencies BRAIN initiative
    • 3.2.2. Investments: The BRAIN INITIATIVE
    • 3.2.3. Investments: BRAIN initiative, DARPA sponsored, Electrical Prescriptions (ElectRx)
    • 3.2.4. Investments: Glaxo Smith Kline interest in Bioelectronic medicine timeline
    • 3.2.5. Investments: Stimulating Peripheral Activity to Relieve Conditions (SPARC)
    • 3.2.6. Investments: Spin-off, Setpoint Medical
  • 3.3. R&D: Bioelectronic Medicine - The Feinstein Institute for Medical Research
  • 3.4. Patents: Increase in the number of patents being filed that pertain to bioelectronic medicines
    • 3.4.1. Patents: Granted by country
  • 3.5. FDA: High percentage PMA & 510K approvals for medical devices
  • 3.6. Societal: Prevalence of Chronic disease
    • 3.6.1. Societal : Ageing population
  • 3.7. Device innovations: Internet of things
    • 3.7.1. Device innovations: IOT, Capabilities
    • 3.7.2. Device innovations: Responsive treatment
    • 3.7.3. Device innovations: Miniaturization
  • 3.8. Trends: Final thoughts

4. MARKET DYNAMICS: RESTRAINTS & CHALLENGES

  • 4.1. Restraints & Challenges: Overview
  • 4.2. Restraints & Challenges: European Union (EU) vs US regulations
  • 4.3. Restraints & Challenges: FDA Approval ( US)
    • 4.3.2. Restraints & Challenges: FDA Approval ( US), Clinical Trial
  • 4.4. Restraints & Challenges: The issue of reimbursement
  • 4.5. Restraints & Challenges: Last resort
  • 4.6. Restraints & Challenges: Final thoughts
  • 4.7. Market by product type

5. CARDIAC BIOELECTRONIC MEDICINES

  • 5.1. Cardiac rhythm management devices : Overview
    • 5.1.1. Cardiac rhythm management devices :Cardiac conduction system overview
    • 5.1.2. Cardiac rhythm management devices : pathway, failure and causes
    • 5.1.3. Cardiac rhythm management devices : Pacemaker
  • 5.2. Bioelectronic medicines: The Components
    • 5.2.1. Bioelectronic medicines: The pulse generator
    • 5.2.2. Pulse generator: Casing & Connector block
    • 5.2.3. Pulse generator: The battery
    • 5.2.4. Pulse generator: Circuitry system
  • 5.3. IPG : Programming
  • 5.4. Bioelectronic medicine: Leads
  • 5.5. Bioelectronic medicines: Electrodes
  • 5.6. Leads: Cardiac rhythm management devices
  • 5.7. Cardiac rhythm management devices : Pacemaker, types
    • 5.7.1. Cardiac rhythm management devices : Pacemaker placement & function in heart
  • 5.8. Cardiac rhythm management devices : ICD
    • 5.8.1. Cardiac rhythm management devices : ICD components
  • 5.9. Cardiac rhythm management devices:ICD, High-Voltage Shock Therapy
    • 5.9.1. Cardiac rhythm management devices : ICD, types
    • 5.9.2. Cardiac rhythm management devices :ICD , How it works in heart
  • 5.10. Cardiac rhythm management devices : Indications for use
  • 5.11. Cardiac rhythm management devices : The players
    • 5.11.1. Medtronic: Cardiac Rhythm
    • 5.11.2. Boston Scientific :Cardiac rhythm
    • 5.11.3. St. Jude Medical: Cardiac rhythm
    • 5.11.4. Sorin & Biotronik: Cardiac Rhythm
  • 5.12. Cardiac Rhythm management devices: Breakdown by vendor
    • 5.12.1. Cardiac Rhythm management devices: ‘Big' three dominance
    • 5.12.2. Cardiac Rhythm management devices (ICD): Sales by territory
    • 5.12.3. Cardiac Rhythm management devices (Pacemaker): Sales by territory
    • 5.12.4. Cardiac rhythm management devices: Comparisons
    • 5.12.5. Cardiac rhythm management devices : Patent analysis
    • 5.12.6. Cardiac rhythm management devices : Patent analysis
  • 5.13. Trends: Cardiac rhythm management devices
  • 5.14. Cardiac rhythm management: Players summary
  • 5.15. Cardiac rhythm management devices : Take home messages

6. ELECTRICAL NEUROMODULATION TECHNOLOGIES : CNS & PNS

  • 6.1. Neuromodulation : Overview
  • 6.2. Timeline: FDA approvals electrical neuromodulation devices (Neurological)
  • 6.3. Neuromodulation: Greater occipital nerve
  • 6.4. Neuromodulation: Sacral Nerve
  • 6.5. Neuromodulation: Vagus Nerve
  • 6.6. Neuromodulation: Trigeminal Nerve
  • 6.7. Neuromodulation: Afferent & Efferent sensory nerves
  • 6.8. Neuromodulation: Spinal Cord
  • 6.9. Neuromodulation: Dorsal root ganglia
  • 6.10. Neuromodulation: Brain
  • 6.11. Neuromodulation: Components & IPG Platform
  • 6.12. Peripheral Nervous System Electro Stimulators
  • 6.13. PNS: Surgically implanted
  • 6.14. Components: Sacral + Vagus neuromodulators
    • 6.14.1. Surgically Implanted PNS stimulators: Depression
    • 6.14.2. Surgically Implanted PNS stimulators: Obesity
    • 6.14.3. Surgically Implanted PNS stimulators: Epilepsy
    • 6.14.4. Surgically Implanted PNS stimulators: Incontinence
    • 6.14.5. Surgically Implanted PNS stimulators: Tinnitus
    • 6.14.6. VNS Therapy System: Depression & Epilepsy
  • 6.15. vBloc® neurometabolic therapy : Weight loss
  • 6.16. InterStim™ system: Bladder control & Fecal Incontinence
  • 6.17. Paired Vagus Nerve Stimulation System : Chronic tinnitus
  • 6.18. Invasive PNS stimulation: Summary
  • 6.19. PNS: Non- Invasive
  • 6.20. Non-Invasive PNS electro stimulators: Transcutaneous electrical nerve stimulation (TENS)
    • 6.20.1. Non-Invasive PNS electro stimulators: ADHD
    • 6.20.2. Non-Invasive PNS electro stimulators: Episodic chronic headache / migraine
  • 6.21. Monarch external Trigeminal Nerve Stimulation : ADHD , Depression and Epilepsy non-invasively
  • 6.22. GammaCore : Episodic cluster headache
  • 6.23. Actipatch: Chronic pain relief
  • 6.24. Quell : Chronic pain
  • 6.25. Summary: Non- Invasive/ minimally invasive electro stimulators
  • 6.26. CNS: Spinal Cord Stimulators & Deep Brain Stimulators
  • 6.27. SCS: Overview
    • 6.27.1. SCS: Components
  • 6.28. NeuroBlock (NeuroStimulation):chronic low back pain
  • 6.29. Axium™ Neurostimulator System : isolated chronic pain of the lower limbs, including the foot, knee, hip or groin
  • 6.30. Reactiv-8 : Disabling chronic back pain
  • 6.31. The Senza® system: Back and leg pain
  • 6.32. SCS: Summary
  • 6.33. DBS :Overview
    • 6.33.1. DBS: Components
    • 6.33.2. DBS: Parkinson Disease
  • 6.34. Activa PC Neurostimulator: Neurological diseases/conditions
  • 6.35. Picostim: Parkinson's disease
  • 6.36. DBS: Summary
  • 6.37. Electrical Neuromodulation technologies: The players
  • 6.38. Electrical Neuromodulation technologies :All neuromodulation devices
    • 6.38.1. Electrical Neuromodulation technologies: By type
    • 6.38.2. Electrical Neuromodulation technologies : SCS
    • 6.38.3. Electrical Neuromodulation technologies : DBS
    • 6.38.4. Electrical Neuromodulation technologies : PNS
    • 6.38.5. Electrical Neuromodulation technologies: Key competitors
  • 6.39. Case study: TENS ( traditional + Advanced)
  • 6.40. Electrical Neuromodulation technologies: The players
    • 6.40.1. Electrical neuromodulation technologies: Patent evolution
    • 6.40.2. Electrical neuromodulation technologies: Trends
    • 6.40.3. Electrical Neuromodulation technologies trends(2) : GiMer Medical
    • 6.40.4. Electrical Neuromodulation technologies trends(3): Nevro
  • 6.41. Key Market players: The big three
  • 6.42. Electrical Neuromodulation technologies: Take home messages

7. OTHER

  • 7.1. Electrical stimulation devices: Other
  • 7.2. Other Electrical stimulation devices: Diabetic foot ulcers
  • 7.3. Other Electrical stimulation devices: Central Sleep Apnea
  • 7.4. DIAPHRAGM PACING SYSTEM: Breathing Disorders (sleep apnea)
  • 7.5. Advanced Microcurrent Technology: Wound Care (diabetic foot ulcers)

8. NEXT GENERATION

  • 8.1. Next Generation bioelectronic medicine
  • 8.2. Interdisciplinary approach
  • 8.3. Next Generation bioelectronic medicines: Creation of a visceral nerve atlas
  • 8.4. Next generation bioelectronic medicines: Neural interfacing technology
  • 8.5. Next generation bioelectronic medicines: Ongoing research for the development of next generation bioelectronic medicines
  • 8.6. "Comprehensive structural and functional mapping of the mammalian cardiac nervous system"
  • 8.7. "Mapping the linkage between auricular vagus nerve receptors and cardiovagal modulation"
  • 8.8. "Soft, conformal wireless optoelectronic systems for the long-term neuromodulation of bladder function"
  • 8.9. "Neuromodulation for asthma"
  • 8.10. Next generation bioelectronic medicines: Summary

9. FULL MARKET FORECAST

  • 9.1. Forecast assumptions: Conclusions
  • 9.2. Market Forecast: Pacemaker units by sales volume
    • 9.2.1. Market Forecast: Pacemaker market value
  • 9.3. Market forecast: ICD units by sales volume
    • 9.3.1. Market forecast: ICD units by market value
  • 9.4. Market forecast: Comparison of pacemaker and ICD unit sales
    • 9.4.1. Market forecast: Comparison of pacemaker and ICD market value
  • 9.5. Market forecast: SCS by unit sales
    • 9.5.1. Market forecast: SCS market value
  • 9.6. Market forecast: DBS by unit sales
    • 9.6.1. Market forecast: DBS market value
  • 9.7. Market forecast: PNS by unit sales
    • 9.7.1. Market forecast: PNS by market value
  • 9.8. Market forecast: SCS ,DBS, PNS unit sales
    • 9.8.1. Market forecast: SCS, DBS ,PNS market value
  • 9.9. Market value traditional TENS by units
    • 9.9.1. Market value Traditional TENS units
  • 9.10. Sales units advanced TENS devices
    • 9.10.1. Market value advanced TENS devices
  • 9.11. Comparison of sales units of Traditional TENS and Advanced TENS
    • 9.11.1. Comparison of market value of Traditonal TENS and Advanced TENS
  • 9.12. Sales units of all termed Bioelectronic Medicines
    • 9.12.1. Market value of all termed bioelectronic medicine

10. FINAL THOUGHTS: TERMED BIOELECTRONIC MEDICINES

  • 10.1. Bioelectronic Medicines: Conclusions

11. COMPANY PROFILES

Back to Top